Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Biotech-bay crawled date : 2021 - 10 - 28 save search
Atara Biotherapeutics to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021
Published: 2021-10-28 (Crawled : 22:00) - biospace.com/
ATRA | $0.7101 -1.18% -1.2% 700K
|
Health Technology
|
| O: 0.2%
H: 4.26%
C: 4.2%
financial results results iot
Sangamo Therapeutics Announces Third Quarter 2021 Conference Call and Webcast
Published: 2021-10-28 (Crawled : 22:00) - biospace.com/
SGMO | News | $0.4911 -5.72% -6.07% 1.2M
|
Health Technology
|
| O: 0.25%
H: 4.31%
C: 4.13%
conference therapeutics
Gilead Sciences Announces Third Quarter 2021 Financial Results
Published: 2021-10-28 (Crawled : 22:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -0.1%
H: 1.44%
C: 0.96%
financial results results
Agilent to Webcast Fourth-Quarter Fiscal Year 2021 Financial Results Presentation
Published: 2021-10-28 (Crawled : 22:00) - biospace.com/
A | $137.49 -1.23% -0.36% 1.6M
|
Health Technology
|
| O: 0.46%
H: 1.16%
C: -0.14%
presentation financial results results
Bio-Rad Reports Third-Quarter 2021 Financial Results
Published: 2021-10-28 (Crawled : 22:00) - biospace.com/
BIO | $278.21 -2.48% 0.0% 210K
|
Health Technology
|
| O: 0.67%
H: 3.26%
C: 2.48%
financial results results
Gilead Announces Clinical Trial Collaboration With Merck to Evaluate Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) in Patients With First-Line Metastatic Triple-Negative Breast Cancer
Published: 2021-10-28 (Crawled : 22:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -0.1%
H: 1.44%
C: 0.96%
collaboration cancer breast cancer trial keytruda
Agilent Companion Diagnostic Expands CE-IVD Mark in Europe to Include Triple-Negative Breast Cancer (TNBC)
Published: 2021-10-28 (Crawled : 22:00) - biospace.com/
A | $137.49 -1.23% -0.36% 1.6M
|
Health Technology
|
| O: 0.46%
H: 1.16%
C: -0.14%
europe cancer breast cancer diagnostic
CytomX Therapeutics to Announce Third Quarter 2021 Financial Results on November 4, 2021
Published: 2021-10-28 (Crawled : 13:15) - biospace.com/
CTMX | $1.635 -2.68% -2.75% 280K
|
Health Technology
|
| O: 1.09%
H: 7.85%
C: 7.22%
financial results results
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.